Tokyo, Sept 2, 2010 (JCN Newswire) - Eisai Co., Ltd. announced today the start of the first patient enrolled clinical study with BAN2401, a novel monoclonal antibody that is being developed as a potential next-generation therapeutic treatment for Alzheimer’s disease. BAN2401 is the first monoclonal antibody to selectively bind, neutralize and eliminate soluble protofibrils, the toxic amyloid-beta aggregates thought to cause Alzheimer’s disease. With this new treatment approach, it is feasible to expect that BAN2401 may have the potential to halt progression of the disease.
